Recent Comments

Comment RSS

GENova Biotherapeutics to obtain three new drug target patents

11. September 2009 04:04

GENova Biotherapeutics, Inc., ("GENova"), a biotechnology company that develops novel therapeutic proteins that disrupt the advance of life-threatening diseases, is pleased to announce that it is in the process of acquiring three promising new drug target patents that could generate over a billion dollar in royalty fees in the mid to long term.

Aaron Whiteman, CEO for GENova says, "Following a rigorous evaluation phase, we have selected three potential blockbuster drug target patents for acquisition, and we look forward to integrating them into our IP portfolio." The acquisition targets still subject to due diligence and contract would include both preclinical and clinical drugs that show promising potential in the major markets of anti-cancer and anti-infective drugs.

GENova will announce details of these new biological products in the coming weeks.

http://www.genovabio.com/

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Add comment



(Will show your Gravatar icon)
  Country flag

biuquote
  • Comment
  • Preview
Loading



News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.